Pyruvate dehydrogenase kinase expression profile is a biomarker for cancer sensitivity to dichloroacetate-mediated growth inhibition.
Gang, B. P.; Rooke, M.; Sun, R. C.; Banskota, S.; Mishra, S.; Dahlstrom, J. E.; Blackburn, A. C.
Show abstract
BackgroundCancer cells favour glycolysis and lactate production over mitochondrial metabolism despite the presence of oxygen (the Warburg effect). Increased pyruvate dehydrogenase kinase (PDK) activity contributes to this glycolytic phenotype. Dichloroacetate (DCA) is a PDK inhibitor with anti-cancer potential that inhibits all four isoforms of PDK but with differing potencies, thus expression of different isoforms may determine sensitivity to DCA. MethodsThe association of sensitivity to growth inhibition by DCA, on-target effects of DCA and expression of all four isoforms of PDKs in a range of epithelial cancer cell lines was investigated in vitro and in vivo. ResultsDCA inhibited growth of cancer cells in vivo and in vitro, reduced pyruvate dehydrogenase phosphorylation and reduced lactate production. The magnitude of the effect of DCA on growth was variable and correlated with the PDK expression profiles of the cells, with low expression of PDK3 (highest Ki for DCA) conferring the highest sensitivity towards DCA. PDK2 siRNA-knockdown inhibited growth to a similar extent to DCA, whilst PDK3 knockdown significantly increased sensitivity to DCA. ConclusionThe PDK expression profile is a potential biomarker for sensitivity to DCA, and should be considered when translating PDK inhibitors into clinical use.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- The efficacy of CB-103, a first-in-class transcriptional Notch inhibitor, in preclinical models of breast cancer 94%
- The differential metabolic signature of breast cancer cellular response to olaparib treatment 94%
- PRMT1 regulates EGFR and Wnt signaling pathways and is a promising target for combinatorial treatment of breast cancer 94%
Similar papers in this journal
- Augmentation of extracellular ATP synergizes with chemotherapy in triple negative breast cancer 95%
- Activity of Estrogen Receptor β Agonists in Therapy-Resistant Estrogen Receptor-Positive Breast Cancer 94%
- Increased efficacy of histone methyltransferase G9a inhibitors against MYCN-amplified Neuroblastoma 93%
Similar papers in this journal
- Targeting wild-type IDH1 enhances chemosensitivity in pancreatic cancer 94%
- Targeting subtype-specific metabolic preferences in nucleotide biosynthesis inhibits tumor growth in a breast cancer model 94%
- Hypoxia driven oncometabolite L-2HG maintains "stemness"-differentiation balance and facilitates immune suppression in pancreatic cancer 93%
Similar papers in this journal
- Selective Impact of ALK and MELK Inhibition on ERα Stability and Cell Proliferation in Cell Lines Representing Distinct Molecular Phenotypes of Breast Cancer 94%
- Periostin facilitates ovarian cancer recurrence by enhancing cancer stemness 93%
- MDM2 inhibitors, nutlin-3a and navtemadelin, retain efficacy in human and mouse cancer cells cultured in hypoxia 93%
Similar papers in this journal
- Inhibitor of the nuclear transport protein XPO1 enhances the anticancer efficacy of KRAS G12C inhibitors in preclinical models of KRAS G12C mutant cancers 93%
- ATR and PKMYT1 inhibition re-sensitize a subset of TNBC patient-derived models to carboplatin inducing mitotic catastrophe 92%
- Targeting the glucose-insulin link in head and neck squamous cell carcinoma induces cytotoxic oxidative stress and inhibits cancer growth 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.